Nivolumab or atezolizumab in the second-line treatment of advanced non-small-cell lung cancer? Prognostic index based on real-world data

被引：0
|
作者：
Knetki-Wroblewska, M. [1 ]
Pluzanski, A. [1 ]
Tabor, S. [1 ]
Winiarczyk, K. [1 ]
Zaborowska-Szmit, M. [1 ]
Zajda, K. [1 ]
Zebrowska, A. Janowicz [1 ]
Piorek, A. [1 ]
Badurak, P. [1 ]
Jaskiewicz, P. [1 ]
Kowalski, D. M. [1 ]
Krzakowski, M. J. [1 ]
机构：
[1] Maria Sklodowska Curie Natl Res Inst Oncol, Lung Canc & Chest Tumors Dept, Warsaw, Poland
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1166
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1040P
引用
收藏
页码：S1030 / S1030
页数：1
相关论文
共 50 条
  • [41] Lung Cancer Prognostic Index Performance in US Real-World Advanced Non-Small Cell Lung Cancer Patients
    Shah, R.
    John, A.
    Alexander, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S391 - S391
  • [42] Second-line treatment options in advanced non-small cell lung cancer
    de Marinis, Filippo
    Ricciardi, Serena
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S258 - S271
  • [43] Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report
    Jumpei Kashima
    Yusuke Okuma
    Ryoko Shimizuguchi
    Kazuro Chiba
    Cancer Immunology, Immunotherapy, 2018, 67 : 61 - 65
  • [44] Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report
    Kashima, Jumpei
    Okuma, Yusuke
    Shimizuguchi, Ryoko
    Chiba, Kazuro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (01) : 61 - 65
  • [45] Efficiency of nivolumab in the treatment of second-line advanced non-squamous non-small cell lung cancer (NSCLC) in Spain
    Gonzalez, P.
    Ortega-Joaquin, N.
    Provencio Pulla, M.
    Garrido, C.
    Echave, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
    Franchi, Matteo
    Pellegrini, Giacomo
    Corrao, Giovanni
    PHARMACEUTICALS, 2022, 15 (04)
  • [47] Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer A Real-World Cost-Effectiveness Analysis
    Cromwell, Ian
    van der Hoek, Kimberly
    Melosky, Barbara
    Peacock, Stuart
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (12) : 2097 - 2103
  • [48] Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: Postmarketing surveillance
    Yamamoto, Nobuyuki
    Nakanishi, Yoichi
    Gemma, Akihiko
    Nakagawa, Kazuhiko
    Sakamoto, Takahiko
    Akamatsu, Ayumi
    Ohe, Yuichiro
    CANCER SCIENCE, 2021, 112 (11) : 4692 - 4701
  • [49] Prognostic Factors in Non-Small-Cell Lung Cancer Treated with Chemoimmunotherapy or Chemotherapy: A Real-World Data Study
    Mostafa, A. A. Bani
    Al-Akhras, A.
    Tashtoush, S.
    Hamouri, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S564 - S564
  • [50] Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study
    Lin, Xinqing
    Deng, Haiyi
    Li, Suyang
    Xie, Xiaohong
    Chen, Chao
    Cai, Longqiu
    Yang, Yilin
    Qiu, Guihuan
    Xie, Zhanhong
    Qin, Yinyin
    Liu, Ming
    Zhou, Chengzhi
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (02) : 757 - 764
12345